Suchergebnisse - (Person:"Piantoni, Silvia")

PubPharm (79)

41

COVID-19 in patients with rheumatic diseases in northern Italy : a single-centre observational and case-control study

enthalten in: The Lancet. Rheumatology | 2020

von Fredi, M. | Cavazzana, I. | Moschetti, L. | +21

42

The rationale for the use of colchicine in COVID-19 : comments on the letter by Cumhur Cure M et al

enthalten in: Clinical rheumatology | 2020

von Piantoni, S. | Colombo, E. | Airò, P. | +6

CommentOn: Clin Rheumatol. 2020 Jul;39(7):2101-2102. - PMID 32394215

43

Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome

enthalten in: medRxiv : the preprint server for health sciences | 2020

von Borghi, M. | Beltagy, A. | Garrafa, E. | +24

UpdateIn: Front Immunol. 2020 Oct 15;11:584241. - PMID 33178218

44

Why not to use colchicine in COVID-19? An oldanti-inflammatory drug for a novel auto-inflammatory disease

enthalten in: Rheumatology (Oxford, England) | 2020

von Piantoni, S. | Patroni, A. | Toniati, P. | +4

CommentOn: Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. - PMID 32374874

45

COVID-19 in rheumatic diseases in Italy : first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)

enthalten in: Clinical and experimental rheumatology | 2020

von Scirè, C. | Carrara, G. | Zanetti, A. | +106

46

The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.

enthalten in: Clinical rheumatology | 2020

von Piantoni, S. | Colombo, E. | Airò, P. | +6

47

The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.

enthalten in: Clinical rheumatology | 2020

von Piantoni, S. | Colombo, E. | Airò, P. | +6

48

The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al.

enthalten in: Clinical rheumatology | 2020

von Piantoni, S. | Colombo, E. | Airò, P. | +6

49

Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?

enthalten in: Clinical and experimental rheumatology | 2020

von Bellan, M. | Andreoli, L. | Nerviani, A. | +6

50

Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls : Are there any differences?

enthalten in: European journal of internal medicine | 2020

von Salvetti, M. | Paini, A. | Andreoli, L. | +8

CommentIn: Eur J Intern Med. 2020 Mar;73:23-24. - PMID 32001097